Comparison of percutaneous and open approach to radiofrequency ablation of colorectal liver metastases in Teaching Hospital Pilsen in 2001−2015
Authors:
J. Brůha 1,2; V. Liška 1,2; R. Pálek 1,2; H. Mírka 2,3; P. Hošek 2; E. Korčáková 3; K. Bajcurová 2,3; J. Fichtl 1; T. Skalický 1; V. Třeška 1
Authors‘ workplace:
Chirurgická klinika LF Univerzity Karlovy a FN Plzeň
přednosta: prof. MUDr. V. Třeška, DrSc.
1; Biomedicínské centrum, LF v Plzni, Univerzita Karlova v Praze
vědecký ředitel: doc. MUDr. M. Štengl, Ph. D.
2; Klinika zobrazovacích metod FN Plzeň
přednosta: prof. MUDr. B. Kreuzberg, CSc.
3
Published in:
Rozhl. Chir., 2016, roč. 95, č. 3, s. 107-111.
Category:
Original articles
Overview
Introduction:
Radiofrequency ablation (RFA) is a well-established method for palliative therapy of unresectable liver tumors. We use an open or percutaneous approach for the treatment of colorectal liver metastases (CLM).
Method:
Clinical data of patients undergoing percutaneous or open RFA for CLM between January 2001 and January 2015 were included in the retrospective study. We evaluated clinical factors for overall survival (OS), no evidence of disease (NED) and non-ablation in relation to tumor sizes and numbers, type of approach and type of used probes.
Results:
147 patients underwent RFA for CLM in this time period. Mean age was 65 years. 168 RFAs were performed in total. OS was influenced by a high number of censors. OS for the first and third years was 93.6% and 61% with no statistical differences between the percutaneous and open approach. NED was significantly shorter in patients with the percutaneous approach. NED was not influenced neither by size nor number of the lesions. A higher risk of non-ablation was observed as statistically significant in patients with percutaneous RFA. A higher, although not statistically significant, risk of non-ablation was also observed for larger metastases. Patients with percutaneous RFA showed a shorter stay in the hospital and fewer complications.
Conclusion:
RFA is an alternative approach to the treatment of unresectable CLM. In our study the open approach was associated with a lower risk of non-ablation. Percutaneous RFA showed a lower risk of complications and a shorter stay in the hospital.
Key words:
radiofrequency ablation − percutaneous RFA − colorectal liver metastases − CLM − palliative therapy
Sources
1. Jarnagin WR, Belghiti J, Blumgart LH (Editors) Blumgart´s surgery of the liver, biliary tract and pancreas. 5th ed., Philadelphia, Saunders/Elsevier 2012.
2. Stoltz A, Gagniere J, Dupré A, et al. Radiofrequency ablation for colorectal liver metastases. J Visc Surg 2014;151:33−44.
3. Abitabile P, Hartl U, Lange J, et al. Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol 2007;33: 67−71.
4. Stang A, Fischbach R, Teichmann W, et al. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer 2009;45:1748–56.
5. Starý L, Klementa I, Zbořil P, et al. Přežívání nemocných po radiofrekvenční ablaci jaterních metastáz kolorektálního karcinomu. Rozhl Chir 2010;12:780−3.
6. Babawale SN, Jensen TM, Frøkjær JB. Long-term survival following radiofrequency ablation of colorectal liver metastases: A retrospective study.World J Gastrointest Surg 2015;7:33−8.
7. Boame N, Gresham G, Jonker D, et al. Use of chemotherapy and radiofrequency ablation to treat colorectal cancer metastases: a retrospective review of The Ottawa Hospital Cancer Centre over 7 years. Curr Oncol 2014;21:557−63.
8. Sofocleous CT, Petre EN, Gonen M, et al. CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy. J Vasc Interv Radiol 2011;22:755−61.
9. Shady W, Petre EN, Gonen M, et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: Factors affecting outcomes-A 10-year experience at a single center. Radiology 2015;12:142489. [Epub ahead of print].
10. Wong J, Lee KF, Yu SC, et al. Percutaneous radiofrequency ablation versus surgical radiofrequency ablation for malignant liver tumours: the long-term results. HPB (Oxford) 2013;15:595−601.
11. Chen EA, Neeman Z, Lee FT, et al. Thermal protection with 5% dextrose solution blanket during radiofrequency ablation. Cardiovasc Intervent Radiol 2006;2:1093−6.
12. Bodily KD, Atwell TD, Mandrekar JN, et al. Hydrodisplacement in the percutaneous cryoablation of 50 renal tumors. AJR Am J Roentgenol 2010;194:779−83.
13. Lee SJ, Choyke LT, Locklin JK, et al. Use of hydrodissection to prevent nerve and muscular damage during radiofrequency ablation of kidney tumors. J Vasc Interv Radiol 2006;17:1967−9.
14. Skalický T, Třeška V, Šnajdauf J, et al. Hepato-pankreato-biliární chirurgie. Praha, Maxdorf Jessenius 2011.
15. Oshowo A, Gillams A, Harrison E, et al. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg 2003;90:1240−3.
16. Třeška V, Skalický T, Ferda J, et al. Resekce jater pro metastázy kolorektálního karcinomu – současnost a perspektivy. Colorectal liver metastases surgery – the present and the perspectives. Rozhl Chir 2014;93:568−71.
Labels
Surgery Orthopaedics Trauma surgeryArticle was published in
Perspectives in Surgery
2016 Issue 3
Most read in this issue
- Atypical, extra pancreatic pseudocyst of the pancreas
- Optimal timing of laparoscopic cholecystectomy in treatment of acute cholecystitis
- Lumbar sympathectomy − literature review over the past 15 years
- Giant aneurysm of the abdominal aorta and iliac arteries